France· FR:69503274
KISPLYX 10 mg, gélule
A medicinal product containing mésilate de lenvatinib, registered in France by EISAI (ROYAUME-UNI), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉSILATE DE LENVATINIB
- Manufacturer
- EISAI (ROYAUME-UNI)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930074961plaquette(s) polyamide aluminium PVC-Aluminium de 30 gélule(s)EUR 1.29
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mésilate de lenvatinib in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKISPLYXEisai GmbH, Frankfurt am Main
- NetherlandsKisplyx 10 mg, harde capsuleEisai GmbH
- FinlandIxedafinSTADA Arzneimittel AG
- SwedenKisplyx 10 mg Kapsel, hårdEisai GmbH
- IrelandKisplyx 10 mg hard capsulesEisai GmbH
- BelgiumIxedafin 10 mgStada Arzneimittel
- SpainKISPLYX 10 MG CAPSULAS DURASEisai Gmbh
- United StatesLenvimaEisai Inc.
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Lenvatinib Accord, Lenvatinib Rcc Sandoz
- Belgium · Ixedafin, Lenvatinib Accord
- Bulgaria · Ленватиниб Виатрис
- Cyprus · Lenvatinib Remedica
- Czechia · Lenvatinib Accord, Lenvatinib Sandoz
- Germany · Lenvatinib Accord, Lenvatinib Hexal
- Denmark · Lenvatinib Accord, Lenvatinib Sandoz
- Estonia · Lenvatinib Remedica, Lenvatinib Sandoz
- Spain · Lenvatinib Accord, Lenvatinib Sandoz
- Finland · Ixedafin, Lenvatinib
- United Kingdom (Northern Ireland) · Lenvatinib, Lenvatinib Thornton & Ross
- Greece · Kynvalib, Lenvatinib Elpen
- Croatia · Lenvatinib Remedica
- Hungary · Lenvatinib Stada
- Ireland · Lenvatinib Accord, Lenvatinib Stada
- Iceland · Kisplyx, Lenvima
- Italy · Lenvatinib Accord, Lenvatinib Sandoz
- Liechtenstein · Kisplyx, Lenvima
- Lithuania · Lenvatinib Sandoz, Lenvatinib Stada
- Luxembourg · Ixedafin, Lenvatinib Olpha
- Latvia · Lenvatinib Sandoz, Lenvatinib Stada
- Malta · Lenvatinib Remedica, Lenvatinib Stada
- Netherlands · Lenvatinib 1a Pharma, Lenvatinib Accord
- Norway · Kisplyx, Lenvatinib Accord
- Portugal · Lenvatinib Accord, Lenvatinib Sandoz
- Sweden · Lenvatinib Accord, Lenvatinib Avansor
- Slovenia · 10 Mg, Lenvatinib Sandoz
- Slovakia · Lenvatinib Pharmevid
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/efd7ded1-c37c-4825-ad3a-284247e9131e GET /v1/drugs/efd7ded1-c37c-4825-ad3a-284247e9131e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69503274",
"date_amm": "2016-08-25",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/16/1128",
"substance": "MÉSILATE DE LENVATINIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mésilate de lenvatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.